Once MSB seals at least one partnership deal with accompanying cash injection in O-6 months time, this will almost certainly negate the need for it raise any further cash via share issue ever again, due to likely outcomes:
A) issue of rare orphan paediatric drug voucher which it can sell for circa 250 - 300 million dollars quite easily. Should be received upon approval of ped acute GVHD by late 2017/ early 2018.
B) Steadily accumulating revenues from Temcell in Japan and from ped acute GVHD in US.
C) milestone payment of ~ 100/150 million upon approval of CHF product in the US. Est. 2018-2019.
Done.
Predictions do come true, page-11
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.015(1.33%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.13 | $1.11 | $672.2K | 602.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7627 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 129178 | 7 |
View Market Depth
| Last trade - 10.10am 18/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |